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This review summarizes observations on the background and potential clinical significance of interference
with follicle stimulating hormone (FSH) regulation of human ovarian function. This interference may occur
at the level of the pituitary by the secretion of FSH isoforms with reduced or absent bioactivtty. In addition,
interference with FSH may occur in the circulation, or within the ovarian follicular compartment. Although
the full range of its significance remains to be elucidated, there are distinct indications that these mechanisms
may be involved in normal ovarian physiology, as well as in abnormal response of the ovary to stimulation
by endogenous FSH or by exogenously-administered gonadotrophin preparations. Moreover, recent advances
in the determination of the structure-function relationship of FSH and FSH-receptor interaction, in combination
with new developments in recombinant DNA technology, will allow the production of modified FSH- or FSH
receptor-like molecules with altered bioactivrty. The availability of FSH agonists and antagonists in the near
future should provide a challenge for clinicians to improve treatment outcome and to find new indications
for the use of these compounds.
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Introduction
The classical endocrine concept teaches that gonadal function
is ruled by pituitary gonadotrophins. Both follicle stimulating
hormone (FSH) and luteinizing hormone (LH) represent a
group of pituitary glycoprotein isohormones. FSH binds to a
specific FSH glycoprotein transmembrane receptor, which is
located exclusively on granulosa cells in ovarian follicles.
Subsequent activation of the G-protein-coupled adenylate
cyclase system results in cell proliferation and differentiated
function. FSH regulates more advanced stages of follicle
development, and may be involved in various forms of human
ovarian dysfunction.
The present review focuses on the background and potential
clinical relevance of substances (either present in the circulation
or locally within the ovarian follicle) which interfere with
normal FSH action (Figure 1). FSH action may be counteracted
in various ways: (i) the wide spectrum of FSH isohormones
may include forms which exhibit FSH antagonist activity by
binding to the FSH receptor without eliciting a response; (ii)
specific anti-FSH antibodies may be present in the circulation
in some patients presenting with premature ovarian failure
or with a reduced response to exogenously administered
gonadotrophins; (iii) various proteins which inhibit FSH action,
either by interfering with binding of FSH to the receptor or at
the level of signal transduction, appear to be present both in
serum and in follicular fluid. In particular, compounds present
in the follicular compartment may be relevant for normal
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ovarian physiology. In addition, pure recombinant human
(rh) FSH, produced by cell lines through recombinant DNA
technology, has recently become available for clinical use.
More insight into the structure-function relationship of glyco-
proteins may allow the production of modified hormones with
specific FSH antagonist activity. This development may have
significant clinical implications.
Structure-function relationship of FSH and FSH
receptors
Gonadotrophic hormones are dimers composed of glycosylated
protein chains. The common a-subunit [which is similar
for all glycoproteins including LH, FSH, thyroid-stimulating
hormone (TSH) and human chorionic gonadotrophin (HCG)]
and the hormone-specific [i-subunit are non-covalently linked
by disulphide bonds. The a-chain consists of 92 amino acids,
whereas human FSHf} contains 111 according to some authors
(Combarnous, 1992) or 118 amino acids according to others
(Catt and Dufau, 1991) (Figure 2, upper panel). The molecular
weight of FSH is -40 kDa, of which 30% consists of
carbohydrates. Oligosaccharide groups are coupled through N-
acetylglucosamine to certain asparagine (Asn) groups at
specific locations of the protein. These glycosylation sites are
located at position 52 and 78 in the a-, and 7 and 24 in the
(J-subuniL Carbohydrate additions to the FSH protein backbone
are branched, consist of mannose, galactose, fucose, and may
end with sialic acid. These side chains determine metabolic
clearance and therefore affect in-vivo biopotency. Differences
in the number of sialic acid residues determine changes in
bioactivity of the isoforms, as will be discussed in the next
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Figure 1. Schematic representation of different levels of potential
interference with follicle stimulating hormone (FSH) in the human
female. (I) pituitary FSH isohormones; (II) interference with
circulating FSH (anti-FSH antibodies; FSH binding inhibitors);
(HI) intra-ovarian interference with FSH [FSH binding inhibitors;
soluble extracellular part of FSH receptor; growth factors
(epidermal growth factor, inhibin, insulin-like growth factor binding
proteins)]; (IV) exogenous FSH antagonists.
section. Carbohydrate additions are not directly involved
in receptor binding, but appear to be important for signal
transduction. The three-dimensional conformation of the hor-
mone (important for hormone-receptor interaction) is main-
tained by disulphide bonds. Specific regions in the polypeptide
subunits (30-45 and 81-92 for a, and 33-53 and 81-95 for
P) which are crucial for hormone-receptor interaction have
recently been identified (Keutmann, 1992). Binding to the
receptor is determined by both the a- and the P-subunit.
Binding specificity is determined exclusively by the P-subunit,
whereas the two binding regions on the subunit appear to be
involved in binding affinity and post-receptor signal transduc-
tion (Combarnous, 1992).
Transmembrane receptors for glycoprotein hormones are
each composed of a large (~700 amino acid residues) single
polypeptide chain. This group of receptors is part of the G-
protein-coupled gene family, and consists of: (i) a large (359
amino acids) hydrophilic N-terminal domain including several
glycosylation sites important for ligand recognition and high
affinity binding; (ii) a highly homologous region comprising
seven transmembrane domains and three intracellular loops;
(iii) a small intracellular C-tenninal domain, important for
signal transduction. Regions corresponding to residues 9-30
and 279-315 of the extracellular domain of the FSH receptor
capable of specifically binding FSH, but not LH or TSH, have
been identified (Dattatreyamurty and Reichert, 1992). A most
interesting study has been published recently (Aittomaki et ai,
1995) concerning some Finnish families who presented with
'hypergonadotrophic ovarian dysgenesis'. Due to a mutation
in exon 7 of the FSH receptor gene, alanine was substituted
for valine at position 189 in the extracellular ligand-binding
domain of the receptor. It was shown that this alteration in the
FSH receptor (situated adjacent to a glycosylation site known
to be essential for FSH ligand binding) resulted in a dramatic
reduction of binding capacity and signal transduction, whereas
ligand binding affinity remained unaltered. This loss of FSH
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Figure 2. Schematic representation of the follicle stimulating
hormone (FSH) glycoprotein structure (upper pannel) and FSH-
receptor interaction (adapted from Combarnous, 1992; bottom
pannel). Asn = asparagine.
receptor function fully explains the phenotype in females.
However, the clinical picture of the male counterparts remains
unclear at this moment. Other workers have failed to show
FSH receptor deletions in a group of unselected women
presenting with premature ovarian failure (Whitney et al.,
1995).
It has been postulated recently that FSH interaction with its
receptor involves initial recognition of the amino terminal
external portion of the receptor by certain regions located
on FSHP (specificity site), followed by three-dimensional
conformational changes in both the hormone and the receptor
allowing the binding of other regions (affinity sites) of the
hormone to the external and transmembrane regions of the
receptor (Figure 2; bottom panel) (Combarnous, 1992; Dias,
1992; Reichert, 1994). The LH receptor contains six potential
glycosylation sites in the extracellular domain. Deglycosylation
of this receptor [expressed in human embryonic kidney (HEK-
293) cells] by site-directed mutagenesis using N-glycanase did
not alter its ligand binding and signal transduction properties
(Tapanainen et aL, 1993). However, intracellular synthesis and
subsequent secretion of the hydrophilic portion may be affected
by glycosylation of the human transmembrane receptor. Sur-
prisingly, the a-subunit and HCGP can be synthesized and
secreted as a single chain, and still maintain biological activity
(Sugahara et al., 1995). This approach using genetically-
engineered gonadotrophin chimera may help to further elucid-
ate the significance of the three-dimensional gonadotrophin
structure for hormone-receptor interaction.
Interference with FSH
Pituitary FSH isohormones
• minor differences in carbohydrate moieties by
changes in posttranslational glycosylation
• similar amino acid composition
same Immunoactivfty
• 15 different isoforms
chromatofocusing; (pH range 3.6-7.6)
• more acidic forms
- decreased receptor binding, and in-vitro bloactlvfty
- enhanced circulating half-fife
Stanton et al.. 1992
UOoaAgukreetal.. 1992
Figure 3. Overview of major observations regarding pituitary
follicle stimulating hormone (FSH) isohormones.
Northern blot analysis has resulted in the detection of several
LH receptor mRNAs of different size. The number of recently-
identified splice variants of the LH and FSH receptor encoding
for a partially intact receptor is growing (Themmen and
Grootegoed, 1994). Regulation of different forms of the
transmembrane receptor may be of physiological relevance, as
will be discussed later. Finally, mutations (resulting in amino
acid substitutions in the transmembrane receptor region) caus-
ing a gain or loss of function of gonadotrophin receptor activity
have been described in the human (for review see Fauser and
Hsueh, 1995). These 'experiments of nature' may also help
to further unravel the structure-function relationship of the
gonadotrophin receptor.
Pituitary FSH isohormones
Recent observations indicate that the anterior pituitary regulates
not only the quantity of secreted hormones, but also its
biopotency by regulating the enzymes involved in post-transla-
tional glycosylation of a- and ^-protein subunits. Glycoprotein
hormones can therefore be synthesized and secreted into the
circulation in many forms. These forms are structurally related
with regard to the protein backbone and therefore have similar
immunoactivity. Using the technique of chromatofocusing
(separating isohormones based on their differences in iso-
electric characteristics) at least 15 (Stanton et al, 1992) forms
of immunoreactive FSH have been detected with isoelectric
points (pi) ranging between 7.6 and 3.6 (Figure 3). Receptor
binding affinity varied with pi value, with the more acidic
forms exhibiting decreased receptor binding and diminished
in-vitro bioactivity (Ulloa-Aguirre et al, 1992). However, the
circulating half-lives of these isoforms were longer.
Altered bioactivity may be detected by in-vitro bioassays,
using secreted oestrogens as the end-point of FSH action
following the addition of serum to cultured rat granulosa or
Sertoli cells. Discrepancies between measured bioactivity and
immunoreactivity (so called B/I ratios) may represent differ-
ences in biopotency due to changes in glycosylation (Chappel,
1995). Biopotency of secreted FSH may be regulated by
steroid feedback, since different isohormone profiles have been
FSH receptor binding inhibitors
• FSH receptor binding inhibitors present in human
serum and follicle fluid
Reichert et a/., 1979: Leeetal., 1990
• Further characterization of binding inhibitors
partial purification, In vttro bioactlvfty, immunoactivity
Leeetal., 1991; Lee et el.. 1993
• Binding inhibitors similar to IGF-BP3 in follicle fluid
deduced from DNA structure and predicted amino acid
sequence Stvmasakigta)., 1990
• Proteins in follicular fluid that share an epitope with
the extracellular domain of the FSH receptor
Dattatreyamurty et al.. 1994
Figure 4. Overview of major observations regarding follicle
stimulating hormone (FSH) receptor binding inhibitors.
detected during the normal menstrual cycle (Padzanabhan
et al, 1988; Zambrano et al, 1995), in women lacking
ovaries (Mason et al, 1992a), and following administration
of gonadotrophin-releasing hormone (GnRH) analogues (for
review see Fauser et al, 1989).
A clear decrease in FSH B/I ratio was observed following
the administration of a GnRH antagonist in normal women
(Dahl et al, 1986). This medication resulted in a substantial
increase in the percentage of basic isohormones. A distinct
rise in FSH immunoreactivity, without a concomitant increase
in bioactivity, was observed in the pH range 9.4—9.6. Moreover,
this fraction clearly inhibited FSH-induced aromatase activity
in vitro, suggesting the presence of naturally-occurring FSH
antagonists in these subjects (Dahl et al, 1988).
Interference with circulating FSH
Circulating FSH binding inhibitors
The presence of a low molecular weight protein in serum
specifically interacting with FSH-receptor binding has been
proposed (Reichert et al, 1979; Dias et al, 1982; Sanzo
and Reichert, 1982) (Figure 4). Indeed, reduction of serum
inhibitory factors is needed for optimal in-vitro measurement of
serum FSH bioactivity. Using the rat granulosa cell aromatase
bioassay, serum samples should be pretreated with polyethylene
glycol (Jia and Hsueh, 1986; Dahl et al, 1989). However, so
far these inhibitor proteins have not been fully characterized
and their physiological significance remains to be determined.
In the near future, the relevance of FSH binding inhibitors
may be studied in more detail using eukaryotic cell lines
[either Chinese hamster ovary (CHO), HEK-293, or COS-7
cells] stably transfected with human FSH receptor cDNA
(Kelton et al, 1992; Tilly et al, 1992; Albanese et al, 1994).
A test system (using FSH-induced cAMP production as the
end point) for specific detection of FSH binding inhibitors
in clinical samples has recently been developed (Schipper
et al, 1995).
Circulating anti-FSH antibodies
The presence of circulating antibodies to human FSH in
some patients receiving exogenous gonadotrophins [human
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menopausal gonadotrophins (HMG)] has been known for quite
some time (Spitz et al, 1973; Tang and Faiman, 1983; Platia
et al, 1984). The presence of anti-FSH antibodies in subjects
with a reduced response to gonadotrophin induction of ovula-
tion have been reported on rare occasions. Interestingly, anti-
FSH antibodies have been detected in 92% of individuals in
a controlled study of 26 low responders of different ages
undergoing ovarian stimulation for in-vitro fertilization (IVF)
using gonadotrophin preparations, whereas none of the good
responders exhibited these antibodies (Meyer et al, 1990).
This concept is appealing, although this study has not been
confirmed by others, and anti-FSH antibodies have not been
characterized in detail. These observations suggest that a low
response to gonadotrophins does not necessarily indicate intra-
ovarian abnormalities such as 'ovarian ageing', as widely
believed at present. Fortunately, recently-published initial
studies applying rhFSH to humans have shown the absence of
anti-FSH antibody formation in these patients (Schoot et al,
1994; Out et al, 1995; Recombinant human FSH study
group, 1995).
Premature ovarian failure results from an absence of ovarian
oocytes (true early menopause). However, in a proportion
of patients, ovaries may be unable to respond normally to
endogenous FSH stimulation, due to the presence of substances
which interfere with FSH. Circulating low molecular weight
FSH receptor binding inhibitors (Chiauzzi et al., 1982; Sluss
and Schneyer, 1992) as well as immunoglobulins that can
block FSH-induced in-vitro granulosa cell DNA synthesis (Van
Weissenbruch et al, 1991) have been described in these women.
However, preliminary studies using human FSH receptor cell
lines do not favour the presence of a high incidence of FSH
blocking agents in women suffering from premature ovarian
failure (Anasti et al, 1995; B.C.J.M.Fauser and A.J.W.Hsueh,
unpublished observations).
Potential for active immunization?
Immunization against HCG is believed to be a viable approach
for the prevention of unwanted reproduction (Aldhous, 1994;
Griffin, 1994). HCGp1 attached to a toxoid (modified bacterial
toxin) induces the formation of antibodies against HCG, which
in turn inhibits HCG support of corpus luteum function and
implantation of the blastocyst. During the last decade several
human studies have been undertaken by the World Health
Organization, but it is still uncertain whether this approach
can be used on a wide scale for female interception.
Monkeys immunized with sheep FSH exhibit an immune
response and subsequent reversible infertility (Sheela Rani
et al, 1978; Murthy et al, 1979; Wickings and Nieschlag,
1980; Srinath et al, 1983; Moudgal et al, 1992). The capacity
of antibodies to neutralize endogenous FSH was more than
adequate, since free FSH could not be detected by radio-
immunoassay. Severe oligozoospermia was rapidly induced
and mating experiments did not result in pregnancies. After
stopping booster injections, fertility was restored in nine out
of 10 monkeys (Moudgal et al, 1992). Human experiments
have not yet been performed, and the question as to whether
this approach might be feasible for human contraceptive
purposes remains to be answered.
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Figure 5. Schematic representation of potential intra-ovarian
regulation of follicle stimulating hormone (FSH) action during the
follicular phase of the human menstrual cycle.
Intra-ovarian interference with FSH
FSH regulation of human follicle development
The intercycle rise in circulating FSH concentrations is caused
by demise of the corpus luteum and reduced negative steroid
feedback actions. If these concentrations surpass a 'threshold'
level, a group of follicles will acquire gonadotrophin depend-
ence and continue their development. This process of follicle
recruitment seems to be under the control of circulating
FSH. Later during the follicular phase a single follicle gains
dominance, reaches the mature Graafian stage and eventually
ovulates (for review see Hodgen, 1982). Decremental serum
FSH concentrations appear to be important for mono-follicle
development (Fauser et al, 1993). As indicated previously,
the FSH isohormone profile might also change during the
follicular phase, with a predominance of basic forms around
mid-cycle (Padmanabhan et al, 1988). Although there is
evidence that basic forms are more biopotent in vitro (Ulloa-
Aquirre, 1992), this may not be the case in vivo (Chappel, 1995).
Significant aromatase activity is only induced in the domin-
ant follicle days after maximum serum FSH concentrations
have been reached (van Santbrink et al, 1995; van Dessel
et al, 1996a). Moreover, enhanced sensitivity of the dominant
follicle to FSH ensures that this follicle continues its develop-
ment despite decreased stimulation from lower FSH concentra-
tions. These observations provide strong, though indirect,
evidence that intra-ovarian modification of FSH action is
crucial for normal ovarian function in the human. It may be
hypothesized that, at the ovarian level, FSH action is either
inhibited by local factors in the early follicular phase or
enhanced in the late follicular phase (see Figure 5).
FSH binding inhibitors present in follicular fluid
Polypeptide modulators may be present in follicular fluid
which block the action of FSH either by inhibiting binding of
Interference with FSH
FSH to its receptor or by blocking postreceptor events induced
by FSH (Ono et al, 1986). A high molecular weight FSH
receptor binding inhibitor has been shown to be present in
human follicular fluid (Lee et al, 1990, 1991, 1993). It has
also been suggested that these proteins share epitopes with the
FSH receptor (Dattatreyamurty et al, 1994), and may therefore
represent a secreted form of the hydrophilic extracellular
domain of the transmembrane receptor. Indeed, recent studies
indicate that alternative DNA splicing encodes for a shorter
receptor protein with a variable length of the extracellular
portion of the receptor (Tsai-Morris et al, 1990; Gromoll
et al, 1992; Themmen and Grootegoed, 1994). Secreted
forms of receptors acting as binding proteins have also been
demonstrated for other hormone systems, including growth
hormone (Leung et al, 1987), insulin (Pezzino et al, 1992)
and TSH (Graves et al, 1993).
Moreover, amino-terminal sequence analysis of the FSH
inhibitor suggests structural similarity with insulin-like growth
factor binding protein 3 (IGF-BP3) (Ling et al, 1990;
Shimasaki et al, 1990). The concept that IGF-BP could directly
inhibit FSH action is intriguing, since IGF-BP3 also binds
IGF (which is produced by granulosa cells and strongly
potentiates FSH action). Finally, purified a-inhibin (which is
present in high concentrations in follicular fluid) also inhibited
FSH binding to FSH receptors in tissue as well as those
expressed in HEK-293 cells (Schneyer et al, 1991).
Auto-paracrine regulation by growth factors
During the last decade much attention has been focused on
potential intra-ovarian regulation of FSH action by (locally-
produced) growth factors (for review, see Fauser and Hsueh,
1988; McNatty et al, 1992; Westergaard, 1992). The majority
of growth factors were shown to enhance FSH-induced
aromatase activity of cultured cells. However, epidermal
growth factor (EGF) (Knecht and Catt, 1983) as well as inhibin
(Miro and Hillier, 1992; Hillier and Miro, 1993) clearly inhibit
FSH action in vitro in non-human primates. Among many
others, IGFs are potent stimulators of FSH-induced differenti-
ated granulosa cell function. Surprisingly, direct anti-FSH
actions have been observed for IGF-BPs, both in vitro (Ui
et al, 1989) and in vivo (Bicsak et al, 1991).
For obvious reasons, human ovarian material is hard to
obtain, and therefore very few experiments have been carried
out using non-IVF human granulosa or theca cell cultures.
IGF-I has been shown to potently enhance FSH-induced
oestrogen production by human granulosa cells in vitro (Mason
et al, 1993). However, it has been demonstrated that EGF has
a strong (Mason et al, 1990) and IGFBP-3 a minor (Mason
etal, 1992b) inhibitory effect on FSH action in vitro. Moreover,
EGF was shown to inhibit, whereas IGF-1 enhanced, the
activity of mRNA encoding the cytochrome P450 aromatase
enzyme in human granulosa cells (Steinkampf et al, 1988),
which is in full agreement with the above-mentioned in-vitro
observations. In the human, intra-follicular concentrations
of EGF decrease with more advanced stages of maturation
(Westergaard, 1992), which supports the concept of a decrease
in intra-ovarian inhibition of FSH action during follicle
development. The IGF-BP profile in follicular fluid has also
been shown to vary during follicle development in the human,
independent of changes in serum concentration (van Dessel
et al, 1996b).
Potential methods of developing anti-FSH
rhFSH with modifed carbohydrate additions
DNA encoding for human a- and FSH f}-subunits has been
transfected into CHO cells, and stable cell lines expressing
the intact FSH dimer (rhFSH) have subsequently been selected
(Keene et al, 1989; Loumaye et al, 1995). rhFSH has an
isohormone profile comparable with that of pituitary or urinary
FSH, with acidic isoforms again showing reduced receptor
affinity and in-vitro bioactivity (Cerpa-Poljak et al, 1993).
Different cell lines may have different glycosylation patterns.
In vitro, rhFSH produced by HEK-293 cells was 3-6 fold
more biopotent due to an increased number of basic isoforms
when compared with a pituitary FSH standard (Flack et al,
1994). A more basic FSH preparation can also be obtained by
selecting a specific pH range, from the entire rhFSH isohormone
profile produced by CHO cells.
Improved knowledge regarding the structure-function rela-
tionship of these glycoproteins, together with novel develop-
ments in recombinant DNA technology, has already resulted
in the development of FSH compounds with altered function.
Chimeric genes were constructed by fusion of the sequence
encoding for the C-terminal peptide (CTP) of the HCG
P-subunit (known to be important for the prolonged half-life
of HCG as opposed to LH) to the translation sequence of the
FSH P-subunit (Fares et al, 1992). The resulting FSH analogue
(FSH-CTP) showed similar receptor binding and in-vitro
bioactivity, but an enhanced circulating half-life and in-vivo
biopotency (LaPolt et al, 1992). This compound is likely to
be clinically relevant, since less rapid clearance may allow
less frequent administration as opposed to daily injections
(Gast, 1995). In addition, single chain gonadotrophin chimera
(where the a- and P-subunits are no longer dimerized)
(Sugahara et al, 1995) may represent a novel approach
for further alteration of structure and function of human
recombinant glycoprotein hormones.
Compounds which block FSH action may be important for
the limitation of severe ovarian hyperstimulation syndrome
(OHSS), if this can be recognized at an early stage. Moreover,
the possibility that an FSH antagonist might prove to be an
effective male or female contraceptive agent is extremely
challenging. Indeed, induction of anti-FSH antibodies has
proved to completely abolish fertility in male monkeys, as
previously discussed. Multiple studies have shown that removal
of all N-linked carbohydrates from pituitary FSH by enzymatic
digestion results in a molecule which exhibits intact receptor
binding, but strongly reduced signal transduction. This com-
pound prevents normal FSH from binding to its receptor and
therefore acts as an antagonist. Presently more refined methods
are available for the modification of carbohydrate additions to
proteins (Boime et al, 1990,1992), including: (i) glycosylation
inhibitors; (ii) site directed mutagenesis (causing loss of
glycosylation at the mutated sites); and (iii) production of
recombinant glycoproteins by mutated cell lines resulting in
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Potential for the development
of FSH antagonists
• Recombinant FSH with modified carbohydrate
additions
(produced by mutant cell Dries or by site directed mutagenesis)
Galway el al., 1990, Bishop etal., 1994; Keeneetal., 1994
• Synthetic peptides corresponding with regions
from FSH potypeptide subunits known to be
important for receptor binding
Santo Coloma et al., 1992. Reichert et al., 1994
• Soluble forms of the extra-cellular domain of the
FSH receptor
Dattatreyamurty etal., 1994
Figure 6. Overview of potential developments which may lead to
the production of follicle stimulating hormone (FSH) antagonists.
selective deletions. This new technology may help in the
production of modified rFSH compounds with altered bio-
potency (see also Figure 6).
Partially-deglycosylated forms of rhFSH produced by mutant
CHO cells (lacking the glycosylation enzyme NAGT or with
defective sialic acid transport systems) exhibit normal receptor
binding, normal in-vitro bioactivity (which indicates normal
signal transduction), but reduced in-vivo bioactivity (sug-
gesting enhanced clearance from the circulation) in the rat
model (Galway et al, 1990). Two recent studies, using site-
directed mutagenes, studied effects of selective deletions of
various oligosaccharides. Deletion of Asn52 in the ot-subunit
results in a 10-fold decrease in-vitro bioactivity. Deletion of
both a-subunit oligosaccharides (52 and 78) also results in a
compound with strongly reduced in-vitro bioactivity, but which
also blocks FSH action (Keene et al, 1994). Furthermore,
deletion of Asn78 on the a-subunit increases receptor binding
affinity by 72%, but removal of other carbohydrates did not
significantly affect receptor binding. Carbohydrates at position
52 on the a-subunit appeared to be important for signal
transduction, whereas deletion of the Asn-linked oligosacchar-
ides at location 7 and 24 of the P-subunit resulted in a distinctly
(216%) increased biopotency (Bishop et al, 1994).
Synthetic peptides
It has been shown that certain regions of the FSH (J-subunit
(region 33-53 and 81-95) (Figure 2) are important for binding
of FSH to the receptor (Santa Coloma and Reichert, 1990).
Therefore, another experimental approach in the development
of FSH antagonists is the production of synthetic peptides
which prevent native FSH from binding to its receptor
(Santa Coloma et al, 1990, 1992; Reichert, 1994). Indeed, a
synthetic peptide corresponding to amino acids 9-30 of the
extracellular domain of the FSH receptor directly binds FSH
(Dattatreyamurty and Reichert, 1992), and inhibits the activity
of the native hormone. This seems to be a very attractive
approach. However, additional studies are needed to decide
whether this will be a viable approach for clinical use.
Extracellular domain of the FSH receptor
The possibility that soluble forms of the extracellular portion
of the FSH receptor may act as circulating ligand binding
proteins suggests synthesis of these proteins as a potential
option for the development of anti-FSH. More studies are
needed to explore this area.
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